Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Table of contents
- Criteria for screening: Wilson and Jungner 1968
- FH diagnosis in family Y
- Confirming FH diagnosis in family Y
- Genetic diagnosis in FH family M
- Cost effectiveness of cascade testing for FH
- Cost effectiveness of GP note searching for FH
- Genomics and the NHS
- How do we get to 25% in 5 years?
- The UK paediatric FH register
- FH children and statins
- Carotid Intima-Media Thickness (cIMT)
- NICE, children and statins: the evidence
- Are statins safe in childhood?
- Universal screening
- Is 95th percentile or 99th percentile the best cut-off?
- Mutation distribution in UK FH adults and children
- NSC reject universal screening proposal
- FH: searching for new genetic causes
- WES in extremes of LDL-C
- The 100,000 Genomes Project
- Monogenic and polygenic causes of high cholesterol
- FH summary: the key issues
- FH research: the timeline
Topics Covered
- Familial hypercholesterolaemia case studies
- NHS 5-year plan for FH
- Universal screening for FH
- Management of children with FH
- Whole Exome Sequencing
- Statins and their use in children
- The 100,000 Genome Project
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Humphries, S. (2023, August 31). Familial hypercholesterolaemia: case studies, universal screening and novel mutations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/CSJM7400.Export Citation (RIS)
Publication History
Financial Disclosures
- Professor Humphries is the Medical Director of StoreGene a UCL spin out company that offers DNA testing for Cardiovascular Disease risk including testing for FH. Professor Humphries is a consultant for Verve Therapeutics, a US based company that is developing gene-editing agents to treat individuals with hypercholesterolaemia, including those with FH.
Familial hypercholesterolaemia: case studies, universal screening and novel mutations
Published on August 31, 2023
28 min
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
In the third part of the talk,
I'm going to go back
to some case studies.
I'll talk a bit about cost-effectiveness
and universal screening,
and about finding
novel genes for FH.
0:17
We're starting this
by pointing out that
there are accepted
criteria for screening
developed by these
two colleagues,
Wilson and Jungner, in 1968.
The condition should be an
important health problem.
The natural history should
be well understood.
It should be detectable
at an early stage.
It should be better to treat
earlier, rather than later.
Suitable and acceptable
tests should be available.
There should be room for
test in clinical services.
The risks should be
less than the benefits,
and the costs should be balanced
against these benefits.
I'm pleased to tell you that FH
meets all of these criteria,
absolutely 100%,
and it really completely
supports the view
that we should be
screening for FH.
1:02
Let's go back to this family,
which I showed you
in the first talk.
The man had had a heart
attack at the age of 35,
and he wanted to know can
we find the genetic cause.
Can we use this information
to see if either son has FH?
The first thing to do is take
a more detailed family tree.
1:20
The pedigree I showed
you is on the left here.
Turns out that his mother had had
a heart attack at the age of 59.
Total cholesterol,
as far as we could make out,
was 7.8.
Turned out that his younger brother
had both high cholesterol, 6.7,
but also had high
triglycerides, 2.5.
And his younger sister had
high cholesterol, 8.7,
and low triglycerides.
When you look, his father
also had high cholesterol
and also high triglycerides.
This is a rather strange
pattern of lipid disorder,
and it raised the question
for us is this truly FH?
Or is it something else called
familial combined hyperlipidemia,
where you see this pattern
of both high triglycerides
and high cholesterol
in the family?
We used our DNA techniques to
screen the LDLR receptor gene.
We found a single base
pair in the LDLR gene,
which alters the proline at
position 685 to leucine.
This is a well-known
FH-causing variation
that's been well-characterised
in many individuals.
Both the original
proband, his mother,
and his sister
carried the mutation.
His father and his
brother did not.
So the question now is,
what about the four children?
You can see that the mean total
cholesterol for children is 4.9.
For FH diagnosis, it
has to be over 6.7.
You can see that at least
a couple of these boys,
they're higher than average,
but none of them are over
the FH diagnostic criteria.
You'd say they probably
don't have FH,
but the DNA test is really the way
to determine this unambiguously.
I'm pleased to say that,
using a DNA assay,
none of the children
carried the mutation.
This is very good news.
All of the four boys were
at 50% chance, each,
of carrying the mutation,
and none of them did.
So we can confirm
the parents have FH.
We can encourage
maintenance of a good diet.
And we can reassure
the boys that,
if they do maintain a
sensible, healthy lifestyle,
they're not going to be at elevated
risk of cardiovascular disease.
Hide